Original Research ARTICLE
Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence of Donor Age and Mild Comorbidities on Phenotypic and Functional Properties.
- 1Berlin-Brandenburg Center for Regenerative Therapies, Charité Medical University of Berlin, Germany
- 2Julius Wolff Institute for Biomechanics and Musculoskeletal Regeneration, Charité Medical University of Berlin, Germany
- 3Department of Transfusion Medicine, Charité Medical University of Berlin, Germany
- 4BIH Core Unit Genomics, Berlin Institute of Health Research (BIH), Germany
- 5Experimental and Clinical Cell Therapy Institute, Spinal Cord Injury & Tissue Regeneration Center, Paracelsus Medical University, Austria
Heterogeneous populations of human bone marrow-derived stromal cells (BMSC) are among the most frequently tested cellular therapeutics to treat degenerative and immune disorders, which occur predominantly in the aging population. Currently, it is unclear, if advanced donor age and commonly associated comorbidities affect the properties of ex vivo-expanded BMSCs. Thus, we stratified cells from adult and elderly donors from our biobank (n=10 and n=13, mean age 38 and 72 years) and compared their phenotypic and functional performance, using multiple assays typically employed as minimal criteria for defining multipotent mesenchymal stromal cells (MSCs). We found that BMSCs from both cohorts meet the MSC standard criteria, exhibiting similar morphology, growth kinetics, gene expression profiles, pro-angiogenic and immunosuppressive potential, and the capacity to differentiate toward adipogenic, chondrogenic and osteogenic lineage. We found no substantial differences between cells from adult and elderly cohorts. As positive controls, we studied the impact of in vitro aging and inflammatory cytokine stimulation. Both conditions clearly affected the cellular properties independent of donor age. We conclude that in vitro aging rather than in vivo donor aging influences BMSC characteristics.
Keywords: cellular therapy, Bone marrow stromal cell (BMSC), Mesenchymal stromal cells (MSCs), aging in vitro, aging in vivo, chronological age, Comorbidity, in vitro potency assays, biobanking
Received: 26 Apr 2019;
Accepted: 03 Oct 2019.
Copyright: © 2019 Moll, Andrzejewska, Souidi, Schoon, Qazi, Sass, Jacobi, Blankenstein, Reinke, Krueger, Streitz, Catar, Kamhieh-Milz, Beez, Krueger, Zemojtel, Jürchott, Strunk, Reinke, Duda and Geissler. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: PhD. Guido Moll, Berlin-Brandenburg Center for Regenerative Therapies, Charité Medical University of Berlin, Berlin, 13353, Baden-Wurttemberg, Germany, firstname.lastname@example.org